UnknownPhase 1NCT02968472

A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The First People's Hospital of Yunnan
Principal Investigator
Huang Jianzhang, Doctor
Shenzhen immune gene therapy research institute
Intervention
prophylactic 4SCAR19 cells(genetic)
Enrollment
30 enrolled
Eligibility
All sexes
Timeline
20152019

Study locations (1)

Collaborators

Shenzhen Geno-Immune Medical Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02968472 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials